RECRUITING

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

Talk to us

Conditions

Heart FailurePolygenic ScoreBeta blockerMetoprolol

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Official Title

Using Polygenic Scores to Guide Beta-blocker Therapy for Heart Failure With Mildly Reduced Ejection Fraction

Quick Facts

Study Start:2025-08-14
Study Completion:2026-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07054489

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18-89 years
  2. * Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
  3. * Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
  1. * Unable to provide informed consent
  2. * Previous documented EF =\< 35%
  3. * Currently on BB \>25% target dose
  4. * Uncontrolled hypertension (systolic BP \> 180 at enrollment)
  5. * Has contraindications to all BB or intolerance to metoprolol
  6. * Systolic BP \< 100 or heart rate \<70
  7. * Current cancer requiring active treatment
  8. * Heart transplant or LVAD or expected in the next year
  9. * Life expectancy \< 1 year for any reason
  10. * Dialysis dependence or ESRD
  11. * MI/ PCI/ CABG within 90 days prior to enrollment or planned in the future
  12. * Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
  13. * If PI decides for any reason participation in trial is not in best interest of the patient

Contacts and Locations

Study Contact

Whitney Cabral, MS
CONTACT
313-949-6616
wcabral1@hfhs.org

Principal Investigator

David Lanfear, MD
PRINCIPAL_INVESTIGATOR
Henry Ford Health

Study Locations (Sites)

Henry Ford Health
Detroit, Michigan, 48202
United States

Collaborators and Investigators

Sponsor: David Lanfear

  • David Lanfear, MD, PRINCIPAL_INVESTIGATOR, Henry Ford Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-14
Study Completion Date2026-08

Study Record Updates

Study Start Date2025-08-14
Study Completion Date2026-08

Terms related to this study

Keywords Provided by Researchers

  • Beta blocker
  • Metoprolol

Additional Relevant MeSH Terms

  • Heart Failure
  • Polygenic Score